Dasatinib (Sprycel)

Indications


Pharmacology

  • Tyrosine Kinase Inhibitor (TKI):

Adverse Effects

Pulmonary Adverse Effects

Pleural Effusion (see Pleural Effusion-Exudate, [[Pleural Effusion-Exudate]])

  • xxx

Pulmonary Hypertension (see Pulmonary Hypertension, [[Pulmonary Hypertension]])

  • Epidemiology
    • Case reports (12 cases confirmed by Swan) indicate a likely association
    • Over 13 cases have been observed in France in 2,900 CML patients treated with dasatinib -> suggests that the lowest estimate incidence of dasatinib-associated pulmonary hypertension is approximately 0.45%
  • Risk Factors
    • Female Sex
    • Prior Treatment with Imatinib (Gleevec) (see Imatinib, [[Imatinib]]): imatinib is also a tyrosine kinase inhibitor
  • Clinical: may occur at any time during treatment
    • Some cases occurred >12 mo after treatment
  • Treatment/Prognosis: discontinue drug -> leads to improvement in some cases
    • Case Series: improvement was observed within 4 mo of drug discontinuation in all but 1 patient (however, after a median follow-up of 9 mo, most patients did not demonstrate complete recovery, and 2 patients died) [MEDLINE]

Other Adverse Effects

  • xxx
  • xxx
  • xxx

References

  • Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukaemia. Leuk Res 2009;33:861–4 [MEDLINE]
  • Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med. 2011 May 23;11:30. doi: 10.1186/1471-2466-11-30 [MEDLINE]
  • Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-. Intern Med. 2012;51(17):2337-40 [MEDLINE]
  • Pulmonary hypertension in patients treated by dasatinib. Circulation 2012;125:2128–37 [MEDLINE]